



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2005. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/657383
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	GLYO-P03-002
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LCM	AG	5,834,442	11/10/98	Raz et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
LCM	BA	EP 0 888 776 A1	07-01-1999	Takara Shuzo Co. Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LCM	CQ	Supplementary European Search Report from application number EP 02 74 9641 dated June 8, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Leigh C. Mair	Date Considered	2-3-06
-----------------------	---------------	--------------------	--------

9485710.1



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	GLYO-P03-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LCM	AH	2003/013684 A1 2003/0013681	01-16-2003	CHANG et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
LCM	BB	WO 00/07624 A	02-17-2000	COLIN et al.		
LCM	BC	WO 00/62076 A	10-19-2000	DOWLING et al.		
LCM	BD	WO 02/057284 A1	07-25-2002	NILSSON et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LCM	CR	International Search Report from application number PCT/US2004/010675 dated August 17, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Leigh C. Main	Date Considered	2-3-06
--------------------	---------------	-----------------	--------

9524872_1.doc



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/657383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	GLYO-P03-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LCM	AQ	US-5,639,737	06/17/97	Rubin	
LCM	AR	US-6,642,205	11/04/03	Klyosov et al.	
LCM	AS	US-6,645,946	11/11/03	Klyosov et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
LCM	BF	WO 02/076474	10-03-2002	Pro-Pharmaceuticals, Inc.		
LCM	BG	WO 02/26262	04-04-2002	Pro-Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
LCM	CQ3	FRANKEL et al. "Synthetic glycoamine analogs synergies with taxol and cisplatin in inducing programmed cell death in ovarian cancer cells", Proc Am Assoc Can Res (1997) 88 th Ann Meeting, abstr. #627		
LCM	CR3	FUJIMOTO et al., "Clinical Outcome of Postoperative Adjuvant Immunochemotherapy with Sioforan for Patients with Resectable Gastric Cancer: a Randomised Controlled Study", Eur J Cancer (1991) 27(9), pp. 1114-1118		
LCM	CS3	GLINSKY et al., "Inhibition of Human Breast Cancer Metastasis in Nude Mice by Synthetic Glycoamines", Cancer Research (1996) 56, pp. 5319-5324.		
LCM	CT3	GLINSKY et al., "Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs", Clin. Exp. Metastasis (1996) 14, pp. 253-267.		
LCM	CU3	GLINSKY, G.V., "Anti-adhesion cancer therapy", Cancer and Metastasis Reviews (1998) 17, pp. 177-185.		
LCM	CV3	GREEN et al., "Adhesion-dependent multicellular drug resistance", Anti-Cancer Drug Design (1999) 14, pp. 153-168.		
LCM	CW3	RAZ, A. et al., "Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis", Cancer and Metastasis Reviews (1987) 6, pp. 433-452.		
LCM	CX3	RENARD et al., "Structure of the repeating units in the rhamnogalacturonic backbone of apple, beet and citrus pectins", Carbohydrate Research (1995) 275, pp. 155-165.		
LCM	CY3	ROS et al., "Extraction, characterisation, and enzymatic degradation of lemon peel pectins", Carbohydrate Research (1996) 282, pp. 271-284.		
LCM	CZ3	ROUND et al., "Investigating the nature of branching in pectin by atomic force microscopy and carbohydrate analysis", Carbohydrate Research (2001) 331, pp. 337-342.		

Examiner Signature	Hugh C. Main	Date Considered	2-3-06
--------------------	--------------	-----------------	--------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/657383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	GLYO-P03-002

LEM	CA4	ZHAN et al., "Scarcity or complete lack of single rhamnose residues interspersed within the homogalacturonan regions of citrus pectin", Carbohydrate Research (1998) 308, pp. 373-380	
-----	-----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Leigh C. Mair	Date Considered	2-3-06
-----------------------	---------------	--------------------	--------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	1	of	5	Attorney Docket Number	GLYO-P03-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LCM	AI	US-6,274,566	08-14-2001	Eliasz et al.	
LCM	AJ	US-6,680,306	01-20-2004	Chang et al.	
LCM	AK	US-2002/0107222	08-08-2002	Platt	
LCM	AL	US-2003/0064957	04-03-2003	Klyosov et al.	
LCM	AM	US-6,500,807	12-31-2002	Platt et al.	
LCM	AN	US-6,258,383 B1	07-10-2001	Gohlke et al.	
LCM	AO	US-5,831,052	11-03-1998	Hillman et al.	
LCM	AP	US-5,498,702	03-12-1996	Mitchell et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
LCM	BE	WO 03/000118	06-21-2002	Chang et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
LCM	CS	APARICIO, A. In vitro cytoinductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12, 220-229 (1998).		
LCM	CT	BOLD, R.J. et al. Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome. J. Surg. Res. 100, 11-17 (2001).		
LCM	CU	BREWER, C.F. Binding and cross-linking properties of galectins. Biochim. Biophys. Acta 1572, 255-262 (2002).		
LCM	CV	BURKE, P.A. et al. Combined Modality Radioimmunotherapy. Cancer 94, 1320-1331 (15 Feb. 2002).		
LCM	CW	CAMBY, I. et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathology 11, 12-26 (2001).		
LCM	CX	CHERAYIL, B.J. et al. Molecular cloning of a human macrophage lectin specific for galactose. PNAS 87, 7324-7328 (Sept. 1990).		
LCM	CY	CHOUFANI, G. et al. The Levels of Expression of Galectin-1, Galectin-3, and the Thomsen-Friedenreich Antigen and Their Binding Sites Decrease as Clinical Aggressiveness Increases in Head and Neck Cancers. Cancer 86, 2353-2363 (1 Dec. 1999).		
LCM	CZ	CINDOLO, L. et al. Galectin-1 and Galectin-3 Expression in Human Bladder Transitional-Cell Carcinomas. Int. J. Cancer 84, 39-43 (1999).		
LCM	CA1	COOPER, D.N.W. Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572,		

Examiner Signature	Heigh C. Main	Date Considered	2-3-06
-----------------------	---------------	--------------------	--------



PTO/SB/08a/b (09-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
		Application Number	10/657,383
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	September 8, 2003
		First Named Inventor	Yan Chang
		Art Unit	1623
		Examiner Name	Not Yet Assigned
Sheet	2	of	5
		Attorney Docket Number	GLYO-P03-002

		209-231 (2002).	
LCM	CB1	DANGUY, A. et al. Galectins and cancer. Biochim. Biophys Acta 1572, 285-293 (2002).	
LCM	CC1	DEL BINO, G. et al. Altered Susceptibility of Differentiating HL-60 Cells to Apoptosis Induced by Antitumor Drugs. Leukemia 8, 281-288 (Feb. 1994).	
LCM	CD1	DIPAOLA, R.S. and Aisner, J. Overcoming bcl-2- and p53-Mediated Resistance in Prostate Cancer. Seminars in Oncology 26, 112-116 (Feb. 1999).	
LCM	CE1	EASTMAN, A. and Rigas, J.R. Modulation of Apoptosis Signaling Pathways and Cell Cycle Regulation. Seminars in Oncology 26, 7-16 (Oct. 1999).	
LCM	CF1	FAN, W. et al. In vitro evaluation of combination chemotherapy against human tumor cells. Oncology Reports 5, 1035-1042 (1998).	
LCM	CG1	FRANCOIS, C. et al. Galectin-1 and Galectin-3 Binding Pattern Expression in Renal Cell Carcinomas. Am. J. Clin. Pathol. 112, 194-203 (1999).	
LCM	CH1	GRANT, S. and Dent, P. Rational integration of agents directed at novel therapeutic targets into combination chemotherapeutic regimens. Curr. Opin. Investigational Drugs 2, 1600-1605 (2001).	
LCM	CI1	GROSS, A. The role of BCL-2 family members in apoptosis. Published by the Department of Biological Regulation, Weizmann Institute of Science, Israel.	
LCM	CJ1	HARA, I. et al. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int. J. Oncol. 17, 1213-1218 (2000).	
LCM	CK1	HERNANDEZ, J.D. and Baum, L.G. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 12, 127R-136R (2002).	
LCM	CL1	HORTOBAGYI, G.N. Recent Progress in the Clinical Development of Docetaxel (Taxotere). Seminars in Oncology 26, 32-36 (June 1999).	
LCM	CM1	HRDLICKOVA, E. et al. Detection of galectin-3 in tear fluid at disease states and immunohistochemical and lectin histochemical analysis in human corneal and conjunctival epithelium. Br. J. Ophthalmol. 85, 1336-1340 (2001).	
LCM	CN1	INOHARA, H. et al. Expression of Galectin-3 in Fine-Needle Aspirates as a Diagnostic Marker Differentiating Benign from Malignant Thyroid Neoplasms. Cancer 85, 2475-2484 (1 June 1999).	
LCM	CO1	INUFUSA, H. et al. Role of galectin-3 in adenocarcinoma liver metastasis. Int. J. Oncol. 19, 913-919 (2001).	
LCM	CP1	JENSEN-JAROLIM, E. et al. Anti-Galectin-3 IgG Autoantibodies in Patients with Crohn's Disease Characterized by Means of Phage Display Peptide Libraries. J. Clin. Immunol. 21(5), 348-356 (2001).	
LCM	CQ1	JOHNSON, K. R. et al. Antagonistic Interplay between Antimitotic and G ₁ -S Arresting Agents Observed in Experimental Combination Therapy. Clin. Cancer Res. 5, 2559-2565 (Sept. 1999).	
LCM	CR1	JULIAO, S. et al. Galectin-3: A Marker and Diagnostic Aid for Chordoma. Present at the 47 th Annual Meeting, Orthopaedic Research Society, February 25-28, 2001, San Francisco, CA.	
LCM	CS1	KARMANOS, Barbara Ann Cancer Institute. Novel Therapeutic Targets & Therapies. www.karmanos.org/we/research/prostate/novel.html retrieved on 1/27/2003.	
LCM	CT1	KILPATRICK, D. C. Animal Lectins: a historical introduction and overview. Biochim. et Biophys. Acta 1572, 187-197 (2002).	
LCM	CU1	KIM, R. et al. A pitfall in the survival benefit of adjustment chemotherapy for node- and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein (Review). Int. J. Oncol. 19, 1075-1080 (2001).	
LCM	CV1	KLASA, R. J. et al. Eradication of Human Non-Hodgkin's Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combine with Low-Dose Cyclophosphamide. Clin. Cancer Res. 6, 2492-2500 (June 2000).	

Examiner Signature	Heigh C. Main	Date Considered	2-3-06
--------------------	---------------	-----------------	--------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	GLYO-P03-002

LCM	CW1	LEFFLER, H. et al. Specificity of Binding of Three Soluble Rat Lung Lectins to Substituted and Unsubstituted Mammalian B-Galactosides. J. Biol. Chem. 261(22), 10119-10126 (5 Aug. 1986).
LCM	CX1	LIM, Y. et al. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem. Biophys. Res. Comm. 295, 119-124 (2002).
LCM	CY1	LINEHAN, W. M. Inhibition of Prostate Cancer Metastasis: a Critical Challenge Ahead. J. Nat. Cancer Inst. 87(5), 331-332 (1 March 1995).
LCM	CX1	LIU, F.-T. et al. Intracellular functions of galectins. Biochim et Biophys Acta 1572, 263-273 (2002).
LCM	CA2	LOPES DE MENEZES, D. E. et al. Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin. Clin. Cancer Res. 6, 2891-2902 (July 2002).
LCM	CB2	LOTZ, M. M. et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. PNAS 90, 3466-3470 (April 1993).
LCM	CC2	MAJLESSIPOUR, F. The Combination Regimen of Idarubicin and Taxotere is Effective Against Human Drug-resistant Leukemic Cell Lines. Anticancer Res. 22, 1361-1368 (2002).
LCM	CD2	MATARRESE, P., et al. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Letters 473, 311-315 (2000).
LCM	CE2	MATARRESE, P., et al. Galectin-3 Overexpression Protects from Apoptosis by Improving Cell Adhesion Properties. Int. Cancer 85, 545-554 (15 Feb. 2000).
LCM	CF2	MEY, A. et al. Expression of the galactose binding protein Mac-2 by human melanoma cell-lines. Cancer Letters 81, 155-163 (1994).
LCM	CG2	NAKAMURA, M. et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int. J. Oncol. 15, 143-148 (1999).
LCM	CH2	NANGIA-MAKKER, P. et al. Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin. J. Nat. Cancer Inst. 94(24) 1854-1862 (18 Dec. 2002).
LCM	CI2	NOVOCASTRA LABORATORIES, LTD. Galectin-3: mouse monoclonal antibody NCL-GAL3.
LCM	CJ2	OHANNESIAN, D. W. et al. Carcinoembryonic Antigen and Other Glycoconjugates Act as Ligands for Galectin-3 in Human Colon Carcinoma Cells. Cancer Res. 55, 2191-2199 (15 May 1995).
LCM	CK2	ONCOLINK: LILLY ONCOLOGY TREATMENT OPTIONS. www.oncolink.com/treatment/section.cfm retrieved on 2/12/2003.
LCM	CL2	ORLANDI, F. et al. Galectin-3 Is a Presurgical Marker of Human Thyroid Carcinoma. Cancer Res. 58, 3015-3020 (15 July 1998).
LCM	CM2	PERILLO, N. L. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 76, 402-412 (1998).
LCM	CN2	PIENTA, K.J. et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J. Nat. Cancer Inst. 87(5), 348-353 (1 March 1995).
LCM	CO2	PLATT, D. and Raz, A. Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin. J. Nat. Cancer Inst. 84, 438-442 (18 March 1992).
LCM	CP2	PUGLIESE, G. The Diabetic Milieu Modulates the Advanced Glycation End Product-Receptor Complexes in the Mesangium by Inducing or Upregulating Galectin-3 Expression. Diabetes 49, 1249-1257 (July 2000).
LCM	CQ2	RABINOVICH, G. A. et al. Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen-Induced Arthritis via T Cell Apoptosis. J. Exp. Med. 190(3), 385-397 (2 Aug. 1999).
LCM	CR2	RABINOVICH, G. A. Role of galectins in inflammatory and immunomodulatory processes. Biochim. Biophys. Acta 1572, 274-284 (2002).
LCM	CS2	RABINOVICH, G. A. et al. The antimetastatic effect of a single low dose of cyclophosphamide

Examiner Signature	Hugh C. Mair	Date Considered	2-3-06
--------------------	--------------	-----------------	--------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	GLYO-P03-002

		involves modulation of galectin-1 and Bcl-2 express. Cancer Immunol. Immunother. 50, 597-603 (2002).	
LCM	CT2	RAYNAUD, F. I. Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice. J. Pharmacol. Exp. Therapeutics 281(1), 420-427 (1997).	
LCM	CU2	RUDIN, C. M. et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 13, 539-545 (2002).	
LCM	CV2	RUITER, G. A. et al. Alkyl-Lysophospholipids as Anticancer Agents and Enhancers of Radiation-Induced Apoptosis. Int. J. Radiation Oncol. Biol. Phys. 49(2), 415-419 (2001).	
LCM	CW2	SANO, H. et al. Human Galectin-3 Is a Novel Chemoattractant for Monocytes and Macrophages. J. Immunol. 165, 2156-2164 (2000).	
LCM	CX2	SAUER, G. et al. New Molecular Targets of Breast Cancer Therapy. Strahlenther. Onkol. 178(3), 123-133 (2002).	
LCM	CY2	SHIH, C. et al. Cryptophycins: A Novel Class of Potent Antimitotic Antitumor Depsipeptides. Curr. Pharm. Des. 7, 1259-1276 (2001).	
LCM	CZ2	SÖRME, P. et al. Low Micromolar Inhibitors of Galectin-3 Based on 3-Derivatization of N-Acetylactosamine. ChemBioChem 3, 183-189 (2002).	
LCM	CA3	TAKAHASHI, T. et al. Mechanisms of the apoptotic activity of CI-F-araA in a human T-ALL cell line, CCRF-CEM. Cancer Chemother Pharmacol. 50, 193-201 (2002).	
LCM	CB3	TENTORI, L. et al. Role of Wild-Type p 53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polymerase. J. Pharmacol. Exp. Therapeutics 285(2), 884-893 (1998).	
LCM	CC3	TORTORA, G. et al. Combined Blockade of Protein Kinase A and Bcl-2 by Antisense Strategy Induces Apoptosis and Inhibits Tumor Growth and Angiogenesis. Clin. Cancer Res. 7, 2537-2544 (Aug. 2001).	
LCM	CD3	TORTORA, G. et al. Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy. Ann. N.Y. Acad. Sci. 968, 139-147 (2002).	
LCM	CE3	TU, S.-M. et al. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Letters 93, 147-155 (1995).	
LCM	CF3	USUDA, J. et al. Increased Cytotoxic Effects of Photodynamic Therapy in IL-6 Gene Transfected Cells via Enhanced Apoptosis. Int. J. Cancer 93, 475-480 (2001).	
LCM	CG3	VIVAT-HANNAH, V. et al. Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel). Cancer Res. 61(24), 8703-8711 (15 Dec. 2001).	
LCM	CH3	WU, X.-X. et al. Enhancement of Fas-mediated Apoptosis in Renal Cell Carcinoma Cells by Adriamycin. Cancer Res. 60, 2912-2918 (1 June 2000).	
LCM	CI3	XIA, F. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin. Radiat. Oncol. 12(4), 296-304 (2002).	
LCM	CJ3	XU, X.-C. et al. Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. Int. J. Oncol. 17, 271-276 (2000).	
LCM	CK3	YAMAMOTO, D. et al. Synergistic action of apoptosis induced by eicosapentaenoic acid and TNP-470 on human breast cancer cells. Breast Cancer Res. Treatment 55, 149-160 (1999).	
LCM	CL3	YAMAOKA, K. et al. Overexpression of A β -Galactoside Binding Protein Causes Transformation of Balb3T3 Fibroblast Cells. Biochem. Biophys. Res. Comm. 179(1), 272-279 (30 Aug. 1991).	
LCM	CM3	YAMAZAKI, K. et al. Simultaneous Induction of Galectin-3 Phosphorylated on Tyrosine Residue, p21 waf1/Cip1/Sdi1, and the Proliferating Cell Nuclear Antigen at a Distinctive Period of Repair of Hepatocytes Injured by CCl4. Biochem. Biophys. Res. Comm. 280, 1077-1084 (2001).	
LCM	CN3	YANG, R.-Y. et al. Expression of galectin-3 modulates T-cell growth and apoptosis. PNAS	

Examiner Signature	<i>Heigh C. Maier</i>	Date Considered	2-3-06
--------------------	-----------------------	-----------------	--------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	5	of	5	Attorney Docket Number	GLYO-P03-002

		93, 6737-6742 (June 1996).	
LCM	CO3	YOSHII, T. et al. Galectin-3 Phosphorylation is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. J. Biol. Chem. 277(9), 6852-6857 (1 March 2002).	
LCM	CP3	ZENG, S. et al. In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cell. Clin. Cancer Res. 6, 3766-3773 (Sept. 2000).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Leigh C. Mair	Date Considered	2-3-06
--------------------	---------------	-----------------	--------

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned 16/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	N/A 1623
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	GLYO-P03-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LCM	AA	US-5,681,923	10-28-1997	Platt	
LCM	AB	US-5,843,442	12-01-1998	Soule et al.	
LCM	AC	US-5,895,784	04-20-1999	Raz et al.	
LCM	AD	US-6,423,314-B2	07-23-2002	Platt	
LCM	AE	US-5,490,991	02-13-1996	Enriquez et al.	
	AF	US-6,600,807	12/2002	Platt et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LCM	CA	Inohara, H. et al., "Effects of Natural Complex Carbohydrate (Citrus Pectin) on Murine Melanoma Cell Properties Related to Galectin-3 Functions," Glycoconjugate Journal 11:527-532 (1994)	
LCM	CB	GBC 590 SafeScience Clinical Data. R&D Focus Drug News, DRUGNL. AN:1186 (2001)	
LCM	CC	Rabinovich G.A. et al., "Galectins and Their Ligands: Amplifiers, Silencers or Tuners of the Inflammatory Response?" Trends in Immunology 23(6):313-320 (2002)	
LCM	CD	Huei-Min Lin et al., "Calectin-3 Mediates Genistein-Induced G2/M Arrest and Inhibits Apoptosis," Carcinogenesis 21(11):1941-1945 (2000)	
LCM	CE	Hyeong-Reh Choi Kim et al., "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," Cancer Research 59:4148-4154 (1999)	
LCM	CF	Pratima Nangia-Makker et al., "Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis," American Journal Pathology 156(3):899-909 (2000)	
LCM	CG	Wen-Qin Zhu et al., "Rapid Release of Intracellular Galectin-3 from Breast Carcinoma Cells by Fetuin," Cancer Research 61:1869-1873 (2001)	
LCM	CH	Vladislav V. Glinsky et al., "Effects of Thomsen-Friedenreich Antigen-specific Peptide P-30 on B-Galactoside-mediated Homotypic Aggregation and Adhesion to the Endothelium of MDA-MB-435 Human Breast Carcinoma Cells," Cancer Research 60:2584-2588 (2000)	
LCM	CI	Vladislav V. Glinsky et al., "The Role of Thomsen-Friedenreich Antigen in Adhesion of human Breast and Prostate Cancer Cells to the Endothelium," Cancer Research 61:4851-4857 (2001)	
LCM	CJ	Hyeong-Reh Choi Kim et al., "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," Cancer Research 59:4148-4154 (1999)	
LCM	CK	Hua Chang Gon et al., "The NH2 Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells," Cancer Research 59:6239-6245 (1999)	

Examiner Signature	Heigh C. Mair	Date Considered	2-3-06
--------------------	---------------	-----------------	--------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned 10/657,383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	N/A 1623
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	GLYO-P03-002

LCM	CL	Pascal O. Berberat et al., "Comparative Analysis of Galectins in Primary Tumors of Tumor Metastasis in Human Pancreatic Cancer," The Journal of Histochemistry & Cytochemistry 49(4):539-549 (2001)	
LCM	CM	Ida Iurisci et al., "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," Clinical Cancer Research 6:1389-1393 (2000)	
LCM	CN	Nachman Mazurek et al., "Phosphorylation of the B-Galactoside-binding Protein Galectin-3 Modulates Binding to its Ligands," The Journal of Biological Chemistry 275(46):36311-36315 (2000)	
LCM	CO	S.E. Baldus et al., "Increased Galectin-3 Expression in Gastric Cancer: Correlations with Histopathological Subtypes, Galactosylated Antigen and Tumor Cell Proliferation," Tumor Biol., 21:258-266 (2000)	
LCM	CP	Matarresse et al., (Abstract) "Galectin-3 Overexpression Protects from Apoptosis by Improving Cell Adhesion Properties," Int. Cancer 85(4):545-554 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Heigh C. Mair	Date Considered	2-3-06
--------------------	---------------	-----------------	--------